Market Overview

UPDATE: Bank of America Downgrades AstraZeneca to Underperform Following Recent Gain

Related AZN
What Are The Best-Selling Drugs Of 2014?
Benzinga's M&A Chatter for Tuesday September 23, 2014
Treasury Develolping Options to Curb Inversions (Fox Business)

Bank of America reduced its rating on AstraZeneca (NYSE: AZN) from Neutral to Underperform while maintaining its price objective at $49.50 a share.

Bank of America commented, "With shares up c10% since mid-year we now have only 6% upside to our PO of £31, the second lowest amongst EU majors. We recognise that AZN's dividend yield of c6.3% remains the highest in EU big-cap pharma, and at the top end of the historic average within the sector. However, the fundamental outlook remains poor (although well recognized) with a 14-17E sales CAGR of minus 5%, recent product launches (Brilinta and Bydureon) remain lackluster, and the late stage pipeline remains weak, in our opinion."

AstraZeneca closed at $46.42 on Friday.

Latest Ratings for AZN

DateFirmActionFromTo
Jul 2014JP MorganReinstatesUnderweight
May 2014BarclaysMaintainsEqual-weight
May 2014DanskeDowngradesBuySell

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (AZN)

Around the Web, We're Loving...

Get Benzinga's Newsletters